About this episode
In The Tox Talks we feature expert injectors with significant experience using botulinum toxins. We explore their experience with particular brands, how their techniques have evolved and the subtle nuances of getting the best out of toxins.
In Chapter 2 we focus on Alluzience (abobotulinumtoxinA), a newly launched toxin developed by Galderma as the world's first ready-to-use liquid toxin. Our guest, dermatologist Dr Christoph Martschin, has been a Galderma KOL since 2011 and is a global speaker and trainer.
We discuss why a liquid toxin was developed, how it differs from traditional toxins, onset and duration, practical benefits of a pre-diluted product, reducing human error, sustainability and waste, managing expectations, pricing and workflow, comfort during injection, and the future of neuromodulators.
What you'll learn
- What makes Alluzience different
- The benefits of a pre-diluted toxin
- Onset and duration compared with other toxins
- Pricing and clinic workflow considerations
Topics
- The Tox Talks
- Botulinum toxin
- Alluzience
- Galderma
- Portugal
Full transcript
The full transcript for this episode is coming soon.